Sanofi SA (EPA: SAN)‘s stock had its “buy” rating restated by investment analysts at Societe Generale in a note issued to investors on Wednesday, StockRatingsNetwork reports. They currently have a €92.00 ($119.48) price objective on the stock.
A number of other analysts have also recently weighed in on SAN. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Sanofi SA in a research note to investors on Tuesday, May 28th. They now have a €102.00 ($132.47) price target on the stock. Separately, analysts at BNP Paribas reiterated an “outperform” rating on shares of Sanofi SA in a research note to investors on Tuesday, May 21st. They now have a €95.00 ($123.38) price target on the stock. Finally, analysts at Oddo & Cie reiterated a “buy” rating on shares of Sanofi SA in a research note to investors on Friday, May 17th. They now have a €91.00 ($118.18) price target on the stock.
Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of €71.89 ($93.37).
Shares of Sanofi SA (EPA: SAN) opened at 80.71 on Wednesday. Sanofi SA has a 52 week low of €54.13 and a 52 week high of €87.03. The stock’s 50-day moving average is currently €25.25. The company has a market cap of €106.8 billion and a P/E ratio of 25.59.
Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs.